Fight Aβ Aggregation with Molecular Aggregates DOI Open Access
Cheng Wang, Dingxin Zhang, Ming Hu

et al.

Macromolecular Chemistry and Physics, Journal Year: 2025, Volume and Issue: unknown

Published: March 5, 2025

Abstract Alzheimer's disease (AD) is the most common form of neurodegenerative disease. Aggregation amyloid‐β peptides (Aβ), a characteristic molecular event AD, may produce neurotoxic aggregates, notably oligomers that can induce series pathogenic change, finally leading to AD. Suppression Aβ aggregates‐induced neurotoxicity via intervention aggregation or removal toxic aggregates are considered as an effective approach for AD treatment. Notably, formed by assembly organic molecules have demonstrated promising potential fight due their advantages, such high binding affinity, blood‐brain barrier permeability, well synergistic effect between multiple functionalities, resulting from unique physicochemical properties in aggregate state. This review focuses on recent progress fighting terms inhibition aggregation, redirection into non‐toxic disassembly and clearance aggregates. Representative examples categorized block manner. Their structural design, working mechanism, anti‐AD highlighted. Finally, perspectives challenges aggregation‐oriented future research also proposed.

Language: Английский

Smart Nano-Hybrid Metal-Organic Frameworks: Revolutionizing Advancements, Applications, and Challenges in Biomedical Therapeutics and Diagnostics DOI Creative Commons
Dilip Kumar Chandra, Awanish Kumar, Chinmaya Mahapatra

et al.

Hybrid Advances, Journal Year: 2025, Volume and Issue: unknown, P. 100406 - 100406

Published: Feb. 1, 2025

Language: Английский

Citations

2
Fight Aβ Aggregation with Molecular Aggregates DOI Open Access
Cheng Wang, Dingxin Zhang, Ming Hu

et al.

Macromolecular Chemistry and Physics, Journal Year: 2025, Volume and Issue: unknown

Published: March 5, 2025

Abstract Alzheimer's disease (AD) is the most common form of neurodegenerative disease. Aggregation amyloid‐β peptides (Aβ), a characteristic molecular event AD, may produce neurotoxic aggregates, notably oligomers that can induce series pathogenic change, finally leading to AD. Suppression Aβ aggregates‐induced neurotoxicity via intervention aggregation or removal toxic aggregates are considered as an effective approach for AD treatment. Notably, formed by assembly organic molecules have demonstrated promising potential fight due their advantages, such high binding affinity, blood‐brain barrier permeability, well synergistic effect between multiple functionalities, resulting from unique physicochemical properties in aggregate state. This review focuses on recent progress fighting terms inhibition aggregation, redirection into non‐toxic disassembly and clearance aggregates. Representative examples categorized block manner. Their structural design, working mechanism, anti‐AD highlighted. Finally, perspectives challenges aggregation‐oriented future research also proposed.

Language: Английский

Citations

0